Substituted boronic acids and boronate esters as immunoproteasome inhibitors

US10294246B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Markus Klein · Weiterstadt, DE
• Oliver Schadt · Rodenbach, DE
• Philipp Haselmayer · Wiesbaden, DE
• Michael Busch · Darmstadt, DE

Key dates

• Filing date: Oct 1, 2015
• Grant date: May 21, 2019
• Expiry date: Oct 1, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.